{Reference Type}: Journal Article
{Title}: Reconsidering the role of depression and common psychiatric disorders as partners in the type 2 diabetes epidemic.
{Author}: Claro AE;Palanza C;Mazza M;Rizzi A;Corsello A;Tartaglione L;Marano G;Schuenemann GEUM;Rigoni M;Pontecorvi A;Janiri L;Muti P;Pitocco D;
{Journal}: World J Diabetes
{Volume}: 15
{Issue}: 6
{Year}: 2024 Jun 15
{Factor}: 4.56
{DOI}: 10.4239/wjd.v15.i6.1374
{Abstract}: Common psychiatric disorders (CPDs) and depression contribute significantly to the global epidemic of type 2 diabetes (T2D). We postulated a possible pathophysiological mechanism that through Bridge-Symptoms present in depression and CPDs, promotes the establishment of emotional eating, activation of the reward system, onset of overweight and obesity and, ultimately the increased risk of developing T2D. The plausibility of the proposed pathophysiological mechanism is supported by the mechanism of action of drugs such as naltrexone-bupropion currently approved for the treatment of both obesity/overweight with T2D and as separate active pharmaceutical ingredients in drug addiction, but also from initial evidence that is emerging regarding glucagon-like peptide 1 receptor agonists that appear to be effective in the treatment of drug addiction. We hope that our hypothesis may be useful in interpreting the higher prevalence of CPDs and depression in patients with T2D compared with the general population and may help refine the integrated psychiatric-diabetic therapy approach to improve the treatment and or remission of T2D.